Aldeyra Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 0.5603 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 33.80M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical ...